Our efforts to promote the use of 1070nm intranasal and transcranial stimulation for prevention of COVID neuroinflammation has now been independently validated by this current report from Univ. of Queensland in Australia regarding changes in Microglial NLRP3 inflammasome activation. This response is associated with neurodegenerative disorders including Alzheimer's and Parkinson's disease and has been the focus of efforts by our collaborators at Durham University. This most recent finding is direct invitro evidence for how SARS COVID 2 virus causes the brain to become inflamed and 'angry' according to the authors Trent Woodruff and Eduardo Albornoz Balmaceda from the university’s School of Biomedical Sciences and virologists from the School of Chemistry and Molecular Biosciences. It was published in Nature’s Molecular Psychiatry.
The Neuradiant 1070nm transcranial photobiomodulation device can help reduce the inflammatory burden as we showed in our recent review article on the subject. (see attached)
We hope to see more efforts undertaken to show the value of light therapy as a way to quickly and safely protect ourselves from the neuroinflammatory damage that comes with COVID. More information at neuronic.online
I've made the point in numerous places that the photobiomodulation dose response curve is not like American capitalism, more is not always better. Here is a very good basic science example that helps support this view. Researchers used different amount of light energy on human skin cells to see how they'd respond. The key result was that the lower power settings produce the most positive change in cell proliferation activity.
Majority people who are now using the Neuradiant 1070+, as well as the Vielight Neuro devices, report benefit from shorter periods of stimulation and do not experience any of the typical overdose responses including headaches, increased sense of congestion and pressure, agitation, irritability, dizziness, and fatigue. This has informed the Neuradiant's titration protocol to start with 3 minutes, then wait 5-10 minutes before continuing for another 3 minutes. The stimulation location, pulse frequency, and intensity are each both programmed based on clinical history, telehealth consultation and quantitative EEG analysis. The dosing schedule often increases over time and can even exceed 20 minutes in some cases to as much as 30 minutes twice daily but always with an eye to recognizing signs of overdose and then adjusting accordingly.
PBM dosing is an evolving process and will become more specific as we evolve our real time neurometric acquisition and anlalytic capability.
What my colleagues and I have been saying for quite some time is now being supported by independent research findings about the value of brainwave biofeedback training as a way to reduce neuroinflammation resulting from chemotherapy. Women being treated for breast cancer engaged in neurofeedback training 3 times a week for up to 9 weeks for a total of 18, 30-minute training sessions. Quantitative EEG and neuropsychological testing was done before and after the training sessions were completed and indicated significant improvement in a range of cognitive and executive function measures. The sample size is too small to draw conclusions but is compelling enough to warrant larger studies. Quietmind Fdn. IRB reviewed a study conducted in 2013 by Jean Alvarez and her colleagues using neurofeedback for breast cancer patients using a different method of neurofeedback and similar results were obtained. We're encouraged to see these findings now coming out of a major academic research university and hope that it will lead to larger trials and hopefully FDA approval and insurance reimbursement.
There is always been a strong debate around the appropriate dosing scheme for achieving the best clinical results with PBM. The paper attached here is showing that lower doses of red light stimulation were more effective in producing positive biological responses including cell proliferation and healthy growth and viability. This lends itself to the idea that the body can use small amounts of stimulation to then self regulate and organize its own healing responses. This aligns with many holistic and integrative health traditions as well as the behavioral medicine models that underpin therapeutic approaches like neurofeedback, acupuncture and homeopathy.
Our experience has long supported these findings as more and more people begin to use the Neuradiant PBM technology. We see a growing percentage of people needing only very brief exposures to the stimulation in order the see significant improvements in cognitive, motor and mood stability. Treatment times can be as brief as 30 seconds to 1 minute a day for people with Parkinson's disease and traumatic brain injury. I find myself repeatedly directing people to cut the dose time in half and reduce the duty cycle to 25-50% instead of the 75% maximum for pulsed stimulation.
I think this allows for a more nuanced model of stimulation delivery that supports the already more targeted method of dosing that incorporates the use of Quantitative EEG assessment.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.